# De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer

> **NCT07421141** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Medical Research Radiological Centre of the Ministry of Health of Russia** · enrollment: 186 (actual)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- Early Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** carboplatin
- **PROCEDURE:** Radical Surgery
- **DRUG:** Adjuvant Systemic Therapy

## Key facts

- **NCT ID:** NCT07421141
- **Lead sponsor:** National Medical Research Radiological Centre of the Ministry of Health of Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-12-10
- **Final completion:** 2028-12-30
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421141, "De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07421141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*